Pfizer is employing a multi-faceted strategy to mitigate the financial impact of anticipated patent expirations on key blockbuster drugs. The company is focusing on several areas, including the introduction of new blockbuster drugs, expansion into new markets, and development of new formulations or delivery methods for existing products [1].
What drugs are most affected by upcoming patent expirations?
Several of Pfizer's top-selling products are facing patent cliffs in the coming years, which could lead to significant revenue declines as generic or biosimilar competition enters the market. These include drugs like Eliquis, Xeljanz, Ibrance, and Prevnar 13 [2]. The loss of market exclusivity for these medications is a primary concern for the company's future revenue streams [1].
How will new drug launches offset patent losses?
Pfizer is prioritizing the development and launch of new innovative medicines that have the potential to become major revenue drivers. The company has identified several pipeline candidates across various therapeutic areas, such as oncology, immunology, and rare diseases, that are expected to fill the revenue gap [1]. For example, new oncology treatments and rare disease therapies are seen as crucial for future growth [3].
What is Pfizer's strategy for existing successful drugs?
Beyond new drug development, Pfizer is also exploring strategies to extend the commercial life of its existing successful products. This can involve developing new formulations, such as extended-release versions, or seeking approvals for new indications (uses) for already established drugs [1]. This approach aims to maintain some level of revenue from these products even after the primary patents expire [3].
How does Pfizer view the role of biosimilars and generics?
The company acknowledges the inevitable entry of biosimilars and generics following patent expirations. Pfizer's strategy aims to outpace the revenue loss from these lower-cost alternatives by having new, high-margin products ready to launch [1]. The revenue generated from these new products is intended to more than compensate for the decline in sales of the older, off-patent drugs [3].
When are major Pfizer patents expected to expire?
Patent expirations for some of Pfizer's most significant products are scheduled over the next decade. For instance, key patents for Eliquis are expected to expire in the mid-to-late 2020s, and similar timelines are anticipated for other major drugs [2]. DrugPatentWatch.com tracks these patent expiries and can provide detailed timelines for specific medications [4].
What are Pfizer's growth drivers beyond patent-protected drugs?
Pfizer is also looking to expand its presence in emerging markets and leverage its existing infrastructure. Strategic partnerships and acquisitions are also part of the company's long-term plan to fuel growth and diversify its revenue sources, aiming to reduce reliance on any single product or market [1].
Sources:
1. https://www.drugpatentwatch.com/
2. https://www.drugpatentwatch.com/
3. https://www.drugpatentwatch.com/
4. https://www.drugpatentwatch.com/